Human Microbiome Market Trends and Global Forecasts 2022-2035: Focus on Therapeutics, Diagnostics and Fecal Microbiota Therapy - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Human Microbiome Market: Focus on Therapeutics, Diagnostics and Fecal Microbiota Therapy: Distribution by Type of Molecule, Type of Product, Target Indication, Therapeutic Areas, Supply Channels and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.

The 'The Human Microbiome Market (4th Edition), 2022-2035' report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of microbiome-based therapeutics, diagnostics and FMTs, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.

One of the key objectives of the report was to estimate the existing market size and future growth opportunity for microbiome therapeutics, diagnostics and FMTs, over the next decade. The research, analyses and insights presented in this report are based on revenue generation trends of the sales, of approved / late stage (estimated) microbiome therapeutics, diagnostic products and FMTs.

The report also features the likely distribution of the current and forecasted opportunity within microbiome therapeutics market across type of molecule (small molecule and biologics), type of product (probiotic and other drug), target indication (graft versus host disease, necrotizing enterocolitis, primary hyperoxaluria and recurrent CDI ), therapeutic area (digestive and gastrointestinal disorders, infectious diseases and rare disorders), route of administration (oral and rectal), key geographical regions.

In order to account for the uncertainties associated with the growth of microbiome market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The ongoing research efforts, focused on targeting and modulating microbiome, have led to the development of treatment options for more than 25 indications. In addition, probiotic therapies with live biotherapeutic products (microbes) are considered to be the most advanced microbiome-based therapies for restoring bacterial symbiosis.

At present, fecal microbiota transplantation (FMT) involving the transfer of complete microbial community from a healthy donor's feces to recipient via oral (in form of a capsule) or rectal (enema and colonoscopy) is the only FDA-approved microbiome therapy, for the treatment of recurrent CDI. However, several players are engaged in developing prescription drugs modulating human microbiome for the treatment of various gastrointestinal and non-gastrointestinal disorders as well.

Further, a number of microbiome diagnostic and screening / profiling tests are commercially available for the detection of different microbiome-related diseases. It is worth mentioning that, owing to the rising interest, a number of start-ups / small firms have established in the past few years and the contributions of big pharma players have fueled the overall growth in this domain.

Driven by increasing prevalence of disease indications, promising therapeutic potential of microbiome-based therapies, encouraging clinical trial results and financial support from the investors, the human microbiome therapeutics and diagnostics market is likely to witness substantial growth in the mid to long-term.

The report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company / organization names):

• Lee Jones (President and Chief Executive Officer, Rebiotix)
• Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic)
• Colleen Cutcliffe (Co-founder and Chief Executive Officer, Pendulum Therapeutics)
• Nikole Kimes (Co-founder and Chief Executive Officer, Siolta Therapeutics)
• James Burges (Co-founder and Vice President of Innovation, Finch Therapeutics)
• JP Benya (Vice President, Operations, Flame Biosciences)
• Debbie Pinkston (Former Vice President, Sales and Business Development, List Biological Laboratories)
• Gregory J Kuehn (Vice President, Business Development and Marketing, Metabiomics)
• Mark Heiman (Chief Scientific Officer and Vice President, Research, Scioto Biosciences)
• Alexander Segal (Founder, Stealth Startup)
• Assaf Oron (Chief Business Officer, BiomX)
• Pierre-Alain Bandinelli (Chief Strategy Officer, Da Volterra)
• Alexander Lin (Associate General Manager, Chung Mei Pharmaceutical)
• Aaron Wright (Senior Scientist, Pacific Northwest National Laboratories)
• Nicholas Monsul (Co-founder and Chairman, Quorum Innovations)
• Charlie Badham (Senior Manager, Corporate Development, 4D Pharma)

Key Questions Answered

• Who are the leading players engaged in the development of microbiome therapeutics?
• Which are the key drugs being developed across various stages of development?
• Which companies are actively involved in conducting clinical trials for microbiome therapeutics and FMTs?
• Who are the leading players engaged in the development of microbiome diagnostics and screening / profiling tests?
• What kind of partnership models are commonly adopted by industry stakeholders?
• Who are the key investors active in the field of human microbiome therapeutics and diagnostics?
• What are the different initiatives undertaken by big pharma players for the development of human microbiome therapeutics in the recent past?
• What is the role of various start-ups engaged in the developing human microbiome therapeutics?
• Which are the most commonly targeted therapeutic indications for microbiome therapeutics are being developed?
• What are the various steps involved in the manufacturing of microbiome therapeutics and what are the key considerations for selecting a CMO / CRO?
• What are the various algorithms / tools used to analyze data generated from microbiome research?
• How is the current and future opportunity, related to microbiome therapeutics, diagnostics and FMT likely to be distributed across key market segments?
• What are the various non-pharma applications of microbiome products?

Key Topics Covered:

1. PREFACE

1.1. Scope of the Report

1.2. Research Methodology

1.3. Key Questions Answered

1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview

3.2. Concept of Microbiota and Microbiome

3.3. Overview of Gut Flora

3.4. The Microbiome and Associated Diseases

3.5. Impact of Microbiota on Drug Pharmacokinetics

3.6. Impact of Microbiota on Therapeutic Outcomes

3.7. Microbiome Therapeutics

3.8. The Human Microbiome Project (HMP)

3.9. Regulatory Guidelines for Live Biotherapeutic Products (LBPs)

3.10. Key Challenges Associated with the Development of Microbiome Therapeutics

3.11. Future Perspectives

4. MICROBIOME THERAPEUTICS: MARKET LANDSCAPE

4.1. Chapter Overview

4.2. Microbiome Therapeutics: Clinical Pipeline

4.3. Microbiome Therapeutics: Preclinical Pipeline

4.4. Microbiome Therapeutics: List of Drug Developers

5. MICROBIOME THERAPEUTICS: COMPANY AND DRUG PROFILES

5.1. Chapter Overview

5.2. Microbiome Therapeutics Developers: Companies with Candidate(s) in Highest Phase of Development

5.3. Finch Therapeutics

5.4. Infant Bacterial Therapeutics

5.5. MaaT Pharma

5.6. OxThera

5.7. Rebiotix (acquired by Ferring Pharmaceuticals)

5.8. Seres Therapeutics

5.9. Microbiome Therapeutics Developers: Companies with Maximum Number of Therapeutic Programs

5.10. 4D Pharma

5.11. Biosortia Pharmaceuticals

5.12. Qu Biologics

5.13. Servatus

6. CLINICAL TRIAL ANALYSIS: HUMAN MICROBIOME THERAPEUTICS

6.1. Chapter Overview

6.2. Human Microbiome Therapeutics: List of Clinical Trials

7. MICROBIOME DIAGNOSTICS AND SCREENING / PROFILING TESTS: MARKET LANDSCAPE

7.1. Chapter Overview

7.2. Overview of Microbiome Diagnostics and Screening / Profiling Tests

7.3. Microbiome Diagnostics and Screening / Profiling Tests: Marketed and Under Development Products

7.4. Microbiome Diagnostic and Screening / Profiling Tests Providers

8. MICROBIOME DIAGNOSTIC AND SCREENING / PROFILING TEST PROVIDERS: COMPANY PROFILES

8.1. Chapter Overview

8.2. Shoreline Biome

8.3. DNA Genotek

8.4. Invivo Healthcare

8.5. GoodGut

8.6. BiomeDx

9. FECAL MICROBIOTA THERAPY (FMT)

9.1. Chapter Overview

9.2. Introduction to Fecal Microbiota Therapy

9.3. Historical Overview

9.4. Fecal Microbiota Therapy: Procedure and Clinical Relevance

9.5. Regulatory Guidelines Related to Fecal Microbiota Therapy

9.6. Insurance Coverage for Fecal Microbota Therapy

9.7. Fecal Microbiota Therapy: Marketed and Development Pipeline

9.8. Fecal Microbiota Therapy: List of Developers

9.9. Stool Banks

10. CLINICAL TRIALS ANALYSIS: FECAL MICROBIOTA THERAPY

10.1. Chapter Overview

10.2. List of Clinical Trials

11. ATTRACTIVENESS COMPETITIVENESS (AC) MATRIX

11.1. Chapter Overview

11.2. AC Matrix: An Overview

11.3. AC Matrix: Analytical Methodology

11.4. AC Matrix: Plotting the Information

11.5. AC Matrix: Analyzing the Data

11.6. Concluding Remarks

12. MICROBIOME RELATED INITIATIVES OF BIG PHARMA PLAYERS

12.1. Chapter Overview

12.2. Scope and Methodology

12.3. Initiatives of Big Pharma Players

12.4. Benchmarking Analysis of Big Pharma Players

13. START-UP HEALTH INDEXING

13.1. Chapter Overview

13.2. Scope and Methodology

13.3. Benchmarking of Start-ups

14. KEY THERAPEUTIC AREAS

14.1. Chapter Overview

14.2. Metabolic Disorders

14.3. Digestive and Gastrointestinal Disorders

14.4. Oncological Indications

14.5. Dermatological Disorders

14.6. Infectious Diseases

15. PARTNERSHIPS AND COLLABORATIONS

15.1. Chapter Overview

15.2. Partnership Models

15.3. Human Microbiome: List of Partnerships and Collaborations

15.4. Analysis by Year of Partnership

15.5. Analysis by Type of Partnership

15.6. Analysis by Year and Type of Partnership

15.7. Analysis by Type of Product

15.8. Analysis by Target Indication

15.9. Analysis by Therapeutic Area

15.10. Analysis by Type of Company

15.11. Analysis by Type of Partner

15.12. Most Active Players: Analysis by Number of Partnerships

15.13. Intercontinental and Intracontinental Agreements

16. FUNDING AND INVESTMENT ANALYSIS

16.1. Chapter Overview

16.2. Types of Funding

16.3. Microbiome Therapeutics and Diagnostics: List of Funding and Investments

17. CASE STUDY: CONTRACT SERVICES FOR MICROBIOME THERAPEUTICS AND LIVE BIOTHERAPEUTICS

17.1. Chapter Overview

17.2. Manufacturing Microbiome Therapeutics

17.3. Key Considerations for Selecting a CMO / CRO Partner

18. BIG DATA AND MICROBIOME THERAPEUTICS

18.1. Chapter Overview

18.2. Introduction to Big Data

18.3. Internet of Things (IoT)

18.4. Growing Interest in Big Data: Google Trends Analysis

18.5. Key Application Areas

18.6. Big Data in Microbiome Research

18.7. Big Data Services for Microbiome Research: List of Companies

18.8. Big Data Services for Microbiome Research: Profiles of Key Players

19. MICROBIOME THERAPEUTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS

19.1. Chapter Overview

19.2. Key Assumptions

19.3. Forecast Methodology

19.4. Global Microbiome Therapeutics Market, 2022-2035

19.5. Microbiome Therapeutics Market: Distribution by Leading Therapeutic Products, 2022-2035

20. MICROBIOME DIAGNOSTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS

20.1. Chapter Overview

20.2. Key Assumptions

20.3 Forecast Methodology

20.4. Global Microbiome Diagnostics Market, 2022-2035

20.5. Microbiome Diagnostics Market: Distribution by Target Indication, 2022-2035

20.6. Microbiome Diagnostics Market: Distribution by Therapeutic Area, 2022-2035

20.7. Microbiome Diagnostics Market: Distribution by Supply Channel, 2022-2035

20.8. Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2022-2035

21. FECAL MICROBIOTA THERAPIES: MARKET FORECAST AND OPPORTUNITY ANALYSIS

21.1. Chapter Overview

21.2. Key Assumptions

21.3. Forecast Methodology

21.4. Overall FMT Market, 2022-2035

21.5. Overall Microbiome Market by Product Offerings, 2022-2035

22. CASE STUDY: MICROBIOME-BASED PRODUCTS IN NON-PHARMACEUTICAL INDUSTRIES

22.1. Chapter Overview

22.2. List of Microbiome Products in Non-Pharmaceutical Industry

22.3. Applications of Microbiome Based Products in Agriculture Industry

22.4. Future Perspectives

23. CONCLUDING REMARKS

24. EXECUTIVE INSIGHTS

24.1 Chapter Overview

24.2. Rebiotix

24.3. S-Biomedic

24.4. Pendulum Therpaeutics

24.5. Siolta Therapeutics

24.6. Finch Therapeutics

24.7 Flame Biociences

24.8. List Biological Laboratories

24.9. Metabiomics

24.10. Scioto Biosciences

24.11. Stealth Startup

24.12. BiomX

24.13. Da Volterra

24.14. Chung Mei Pharmaceutical

24.15. Pacific Northwest National Laboratories

24.16. Quorum Innovations

24.17. 4D Pharma

25. APPENDIX I: TABULATED DATA

26. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/r/e76rq7

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900